CUPERTINO, Calif.,
(Nasdaq: DRRX) announced today that
will be presenting at the
on
(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)
A live audio webcast of the presentation will be available by accessing
are unable to participate during the live webcast, the call will be archived
on
About
innovative drugs for pain and other chronic diseases, with late-stage
development programs including REMOXY(TM), POSIDUR(TM), ELADUR(TM), and
TRANSDUR(TM)-Sufentanil.
injectable depot delivery technologies enable new indications and superior
clinical/commercial attributes such as abuse deterrence, improved convenience,
compliance, efficacy and safety for small molecule and biologic drugs. For
more information, please visit www.www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are
trademarks of
respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug
candidates under development and have not been approved for commercialization
by the
SOURCE
CONTACT:
Corporation
Photo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
Web Site: http://www.www.durect.com